Menveo Injection, Solution
Product Images NDC 58160-827

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Menveo (NDC 58160-827). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Biologicals Sa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Menveo Figure 1 (Menveo Spl Graphic 01)

An instructional illustration showing the MenCYW-135 liquid conjugate component vial attached to a syringe. A black arrow pointing downward indicates the step of drawing liquid from the vial into the syringe, part of preparing the Menveo meningococcal conjugate vaccine kit.*

FDA Label Image

Menveo Figure 2 (Menveo Spl Graphic 02)

An instructional illustration showing a syringe positioned above a vial labeled with the number 2. The vial is identified as containing MenA lyophilized conjugate component (powder) of the Menveo vaccine kit by GlaxoSmithKline Biologicals SA. A downward arrow indicates the syringe is to be inserted into the vial.*

FDA Label Image

Menveo Figure 3 (Menveo Spl Graphic 03)

Illustration showing the technique of tilting a syringe with a needle attached, demonstrated in three sequential positions with arrows indicating the direction of movement. Each syringe is labeled with the number 2 on the cap.*

FDA Label Image

Menveo Figure 4 (Menveo Spl Graphic 04)

An instructional diagram depicting the preparation of Menveo vaccine, showing a syringe drawing 0.5 mL of reconstituted vaccine from a vial labeled with the number 2. Arrows indicate the direction for syringe use during vaccine reconstitution.*

FDA Label Image

Menveo Carton (Menveo Spl Graphic 05)

Menveo meningococcal vaccine kit label shows it contains 5 vials of MenCYW-135 Liquid Conjugate Component and 5 vials of MenA Lyophilized Conjugate Component. The vaccine is indicated for use from 2 months through 55 years of age, with a single dose of 0.5 mL after reconstitution. Labeler is GlaxoSmithKline Biologicals SA.*

FDA Label Image

Menveo Mena Vial Label (Menveo Spl Graphic 06)

Menveo Kit label including information for the MenA Lyophilized Conjugate Component vial (1 of 2). The label indicates it should not be used alone and instructs to reconstitute with the MenCYW-135 Liquid Conjugate Component (vial 1) to form Menveo. Provided by GSK Vaccines, Srl, with NDC 58160-958-01.*

FDA Label Image

Menveo Mencyw-135 Vial Label (Menveo Spl Graphic 07)

Label for MenCYW-135 Liquid Conjugate Component, part of the Menveo vaccine kit by GlaxoSmithKline Biologicals SA. This vial is labeled as 1 of 2, with instructions that it is not to be used alone but combined with MenA Lyophilized Conjugate Component (Vial 2) to form Menveo. The label includes NDC 58160-959-01 and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.